260258-92-2

Basic information

• Product Name: 4-(1-phenyl-1H-benzoimidazol-5-yl)-1H-pyridin-2-one
• Synonyms: 4-(1-phenyl-1H-benzoimidazol-5-yl)-1H-pyridin-2-one
• CAS NO: 260258-92-2
• Molecular Weight: 287.321
• Mol File: 260258-92-2.mol

Chemical Properties

• CAS DataBase Reference: 4-(1-phenyl-1H-benzoimidazol-5-yl)-1H-pyridin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-phenyl-1H-benzoimidazol-5-yl)-1H-pyridin-2-one(260258-92-2)
• EPA Substance Registry System: 4-(1-phenyl-1H-benzoimidazol-5-yl)-1H-pyridin-2-one(260258-92-2)

Safety Data

• Hazardous Substances Data: 260258-92-2(Hazardous Substances Data)

Upstream product

• 260258-91-1 1-phenyl-5-pyridin-4-yl-1H-benzoimidazole 
• 221636-18-6 5-Bromo-1-phenyl-1H-benzoimidazole 
• 62-53-3 aniline 
• 68765-53-7 4-bromo-N¹-phenyl-1,2-benzenediamine 
• 16588-25-3 4-bromo-2-nitro-N-phenylaminobenzene 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 1120-87-2 4-bromopyridin 

Relevant articles and documents

Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR

1,5-Diarylbenzimidazoles have been identified as potent inhibitors of KDR kinase activity. The series was developed with a goal of finding compounds with optimal drug-like properties. This communication describes structural modifications in the series that enhance solubility, lower protein binding, and provide compounds with excellent potency and pharmacokinetic profiles.

Angiogenesis inhibitors

The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tryrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.

Tyrosine kinase inhibitors

The present invention relates to benzinidazole compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.